fluoxetine has been researched along with Vomiting in 13 studies
Fluoxetine: The first highly specific serotonin uptake inhibitor. It is used as an antidepressant and often has a more acceptable side-effects profile than traditional antidepressants.
fluoxetine : A racemate comprising equimolar amounts of (R)- and (S)-fluoxetine. A selective serotonin reuptake inhibitor (SSRI), it is used (generally as the hydrochloride salt) for the treatment of depression (and the depressive phase of bipolar disorder), bullimia nervosa, and obsessive-compulsive disorder.
N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propan-1-amine : An aromatic ether consisting of 4-trifluoromethylphenol in which the hydrogen of the phenolic hydroxy group is replaced by a 3-(methylamino)-1-phenylpropyl group.
Vomiting: The forcible expulsion of the contents of the STOMACH through the MOUTH.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To evaluate fluoxetine efficacy in the treatment of bulimia nervosa patients with or without comorbid depression." | 9.09 | Effectiveness of fluoxetine therapy in bulimia nervosa regardless of comorbid depression. ( al-Banna, M; Ascroft, RC; Goldstein, DJ; Wilson, MG, 1999) |
| "A randomized, placebo-controlled study was conducted examining the singular and combined effects of fluoxetine and a self-help manual on suppressing bulimic behaviors in women with bulimia nervosa." | 9.09 | The relative efficacy of fluoxetine and manual-based self-help in the treatment of outpatients with bulimia nervosa. ( Al-Banna, M; Crosby, R; Fletcher, L; Hanson, K; Mitchell, JE; Mussell, MP; Seim, H, 2001) |
| "Selective serotonin reuptake inhibitors fluvoxamine and fluoxetine, as well as serotonin (5-HT), induced vomiting in Suncus murinus (a house musk shrew)." | 7.72 | Possible involvement of peripheral serotonin 5-HT3 receptors in fluvoxamine-induced emesis in Suncus murinus. ( Baba, J; Fujiwara-Sawada, M; Imanishi, T; Yoshida, A, 2003) |
| "The purpose of this study was to establish whether vomiting bulimic and/or non-bulimic depressive patients, both treated with the serotonin reuptake inhibitor SI-5-HT (fluoxetine), have differing proportions of inorganic components (specifically, sodium, potassium and calcium) in their parotid salivary gland secretions, than in the average population." | 5.17 | Parotid gland flow activity and inorganic composition in purging bulimic patients treated with fluoxetine. ( Linden, RW; Paszynska, E; Rajewski, A; Slopien, A, 2013) |
| "To evaluate fluoxetine efficacy in the treatment of bulimia nervosa patients with or without comorbid depression." | 5.09 | Effectiveness of fluoxetine therapy in bulimia nervosa regardless of comorbid depression. ( al-Banna, M; Ascroft, RC; Goldstein, DJ; Wilson, MG, 1999) |
| "A randomized, placebo-controlled study was conducted examining the singular and combined effects of fluoxetine and a self-help manual on suppressing bulimic behaviors in women with bulimia nervosa." | 5.09 | The relative efficacy of fluoxetine and manual-based self-help in the treatment of outpatients with bulimia nervosa. ( Al-Banna, M; Crosby, R; Fletcher, L; Hanson, K; Mitchell, JE; Mussell, MP; Seim, H, 2001) |
| "The current study established whether vomiting bulimic and/or non-bulimic depressive patients, both treated with a serotonin reuptake inhibitor (fluoxetine), have changes in their whole salivary secretion and inorganic components: Na(+), K(+), Ca(2+)." | 3.77 | Flow rates and inorganic composition of whole saliva in purging bulimic patients treated with a fluoxetine. ( Linden, RW; Paszynska, E; Rajewski, A; Slopien, A, 2011) |
| "Selective serotonin reuptake inhibitors fluvoxamine and fluoxetine, as well as serotonin (5-HT), induced vomiting in Suncus murinus (a house musk shrew)." | 3.72 | Possible involvement of peripheral serotonin 5-HT3 receptors in fluvoxamine-induced emesis in Suncus murinus. ( Baba, J; Fujiwara-Sawada, M; Imanishi, T; Yoshida, A, 2003) |
| " The present study investigated potential modifications to the pharmacokinetic profile of milnacipran at steady-state when it is substituted for fluoxetine without any washout period." | 2.72 | Lack of pharmacokinetic interaction when switching from fluoxetine to milnacipran. ( Chassard, D; Hermann, P; Puozzo, C, 2006) |
| " These children will have no adverse effects or only minimal effects and require no emergency treatment or gastric decontamination." | 1.32 | Fluoxetine exposures: are they safe for children? ( Baker, SD; Morgan, DL, 2004) |
| "Litoxetine has moderate affinity for cerebral 5HT3 receptors (Ki = 85 nM), while fluoxetine, similar to other 5HT uptake inhibitors, has only negligible affinity for this receptor (Ki = 6." | 1.29 | Litoxetine: a selective 5-HT uptake inhibitor with concomitant 5-HT3 receptor antagonist and antiemetic properties. ( Angel, I; Garreau, M; Langer, SZ; Prouteau, M; Schoemaker, H, 1993) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 4 (30.77) | 18.2507 |
| 2000's | 4 (30.77) | 29.6817 |
| 2010's | 3 (23.08) | 24.3611 |
| 2020's | 2 (15.38) | 2.80 |
| Authors | Studies |
|---|---|
| Yu, S | 1 |
| Zhang, Y | 1 |
| Shen, C | 1 |
| Shao, F | 1 |
| Christodoulos, IN | 1 |
| Chyou, TY | 1 |
| Nishtala, PS | 1 |
| Paszynska, E | 2 |
| Linden, RW | 2 |
| Slopien, A | 2 |
| Rajewski, A | 2 |
| van der Toorn, M | 1 |
| de Klerk, S | 1 |
| Fujiwara-Sawada, M | 1 |
| Imanishi, T | 1 |
| Yoshida, A | 1 |
| Baba, J | 1 |
| Baker, SD | 1 |
| Morgan, DL | 1 |
| Puozzo, C | 1 |
| Hermann, P | 1 |
| Chassard, D | 1 |
| Lester, BM | 1 |
| Cucca, J | 1 |
| Andreozzi, L | 1 |
| Flanagan, P | 1 |
| Oh, W | 1 |
| Angel, I | 1 |
| Schoemaker, H | 1 |
| Prouteau, M | 1 |
| Garreau, M | 1 |
| Langer, SZ | 1 |
| De Wilde, J | 1 |
| Spiers, R | 1 |
| Mertens, C | 1 |
| Bartholomé, F | 1 |
| Schotte, G | 1 |
| Leyman, S | 1 |
| Goldstein, DJ | 1 |
| Wilson, MG | 1 |
| Ascroft, RC | 1 |
| al-Banna, M | 2 |
| Mitchell, JE | 1 |
| Fletcher, L | 1 |
| Hanson, K | 1 |
| Mussell, MP | 1 |
| Seim, H | 1 |
| Crosby, R | 1 |
1 review available for fluoxetine and Vomiting
| Article | Year |
|---|---|
Efficacy of pharmacotherapies for bulimia nervosa: a systematic review and meta-analysis.
Topics: Bulimia; Bulimia Nervosa; Fluoxetine; Humans; Selective Serotonin Reuptake Inhibitors; Vomiting | 2023 |
5 trials available for fluoxetine and Vomiting
| Article | Year |
|---|---|
Parotid gland flow activity and inorganic composition in purging bulimic patients treated with fluoxetine.
Topics: Adult; Bipolar Disorder; Bulimia; Calcium; Female; Fluoxetine; Humans; Parotid Gland; Potassium; Sal | 2013 |
Lack of pharmacokinetic interaction when switching from fluoxetine to milnacipran.
Topics: Adult; Area Under Curve; Cyclopropanes; Cytochrome P-450 CYP2D6; Drug Administration Schedule; Drug | 2006 |
A double-blind, comparative, multicentre study comparing paroxetine with fluoxetine in depressed patients.
Topics: Adolescent; Adult; Depressive Disorder; Double-Blind Method; Female; Fluoxetine; Humans; Male; Middl | 1993 |
Effectiveness of fluoxetine therapy in bulimia nervosa regardless of comorbid depression.
Topics: Adult; Antidepressive Agents, Second-Generation; Bulimia; Comorbidity; Depressive Disorder; Double-B | 1999 |
The relative efficacy of fluoxetine and manual-based self-help in the treatment of outpatients with bulimia nervosa.
Topics: Adolescent; Adult; Analysis of Variance; Antidepressive Agents, Second-Generation; Bulimia; Fluoxeti | 2001 |
7 other studies available for fluoxetine and Vomiting
| Article | Year |
|---|---|
Safety of fluoxetine use in children and adolescents: a disproportionality analysis of the Food and Drug Administration Adverse Event Reporting System (FAERS) database.
Topics: Adolescent; Adverse Drug Reaction Reporting Systems; Antidepressive Agents, Second-Generation; Anxie | 2020 |
A 43-year-old woman with a quadriparesis.
Topics: Acidosis; Adult; Atrioventricular Block; Crohn Disease; Female; Fluoxetine; Humans; Hypokalemia; Ile | 2016 |
Flow rates and inorganic composition of whole saliva in purging bulimic patients treated with a fluoxetine.
Topics: Adult; Antidepressive Agents, Second-Generation; Bulimia; Calcium; Colorimetry; Depression; Electrol | 2011 |
Possible involvement of peripheral serotonin 5-HT3 receptors in fluvoxamine-induced emesis in Suncus murinus.
Topics: Animals; Dose-Response Relationship, Drug; Female; Fluoxetine; Fluvoxamine; Male; Selective Serotoni | 2003 |
Fluoxetine exposures: are they safe for children?
Topics: Acute Disease; Age Distribution; Child Welfare; Child, Preschool; Coma; Diarrhea; Dose-Response Rela | 2004 |
Possible association between fluoxetine hydrochloride and colic in an infant.
Topics: Adult; Breast Feeding; Colic; Crying; Feeding Behavior; Female; Fluoxetine; Humans; Infant, Newborn; | 1993 |
Litoxetine: a selective 5-HT uptake inhibitor with concomitant 5-HT3 receptor antagonist and antiemetic properties.
Topics: Animals; Antiemetics; Binding, Competitive; Cerebral Cortex; Cisplatin; Dose-Response Relationship, | 1993 |